Cointime

Theraly Fibrosis

company

About

Theraly is a preclinical-stage company whose mission is to develop innovative treatments for various forms of fibrotic disease.

  • 11 - 50

Highlights

Total Funding Amount
$3.90M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
$3.90M
Industries
Biopharma,Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

Theraly is a preclinical-stage company whose mission is to develop innovative treatments for various forms of fibrotic disease including chronic pancreatitis, systemic sclerosis, and NASH. The company’s lead candidate, TLY012, selectively targets myofibroblasts, cells believed to be the critical originators of fibrosis, a condition that affects a variety of tissues.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$3.90M
Theraly Fibrosis has raised a total of $3.90M in funding over 2 rounds. Their latest funding was raised on Jan 30, 2020 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 30, 2020 Grant $3.90M 1 National Institutes of Health — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Theraly Fibrosis is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
Cointime
เนื้อหา
บริษัท